ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Bo... 15/06/2021 Healthcare Recruitment ongoing in Europe. Primary objectives: to assess the effect of vafidemstat to address agitation and... Partners - Oryzon Genomics
ORYZON presents iadademstat ALICE 30-month data at EHA-2021, confirming positive and robu... 11/06/2021 Healthcare Robust signals of clinical efficacy, with ORR of 83%, of which 67% are CR/CRi and five patients with responses longer... Partners - Oryzon Genomics
Vaccines Manufacturing: COVID-19 and Beyond On-line Del 09/06/2021 to 09/06/2021 Healthcare Access to innovation Coronavirus
OWL Metabolomics and Sagimet Biosciences closed an agreement to use OWL´s services in Sagi... 27/05/2021 Healthcare In a recent Phase 2a trial, TVB-2640 improved serum biomarkers of liver injury in patients with nonalcoholic... Partners
WEBINAR: EU Strategy on COVID-19 Treatments On-line Del 20/05/2021 08:30 to 20/05/2021 10:00 Healthcare Coronavirus
ORYZON to present new clinical data and corporate updates at international conferences in... 13/05/2021 Healthcare The conferences are: BioEquity Europe Digital, Foro Medcap BME 2021, Oxford Global’s Online Drug Discovery Week... Partners - Oryzon Genomics
Advances in Neuroimmunology: Promise for Novel Therapeutics for CNS Disorders On-line Del 30/06/2021 15:00 to 30/05/2021 17:30 Healthcare Access to innovation
